Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT‐AF II

Background Nonvitamin K oral anticoagulants require dose adjustment based on kidney function.The most common estimate of kidney function employed in clinical practice is estimated glomerular filtration rate (eGFR); however, product monographs recommend the use of the Cockcroft-Gault estimated creati...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of the American Heart Association Ročník 12; číslo 6; s. e026605
Hlavní autori:	Yao, Ren Jie Robert, Holmes, DaJuanicia N., Andrade, Jason G., Levin, Adeera, Piccini, Jonathan P., Fordyce, Christopher B.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England John Wiley and Sons Inc 21.03.2023 Wiley
Predmet:	Administration, Oral Anticoagulants - therapeutic use atrial fibrillation Atrial Fibrillation - complications Atrial Fibrillation - diagnosis Atrial Fibrillation - drug therapy Dabigatran Humans nonvitamin K oral anticoagulant ORBIT‐AF II Original Research renal dose adjustment Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - diagnosis Renal Insufficiency, Chronic - epidemiology Rivaroxaban Stroke - diagnosis Stroke - epidemiology Stroke - etiology ORBIT‐AF II atrial fibrillation nonvitamin K oral anticoagulant renal dose adjustment
ISSN:	2047-9980, 2047-9980
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Background Nonvitamin K oral anticoagulants require dose adjustment based on kidney function.The most common estimate of kidney function employed in clinical practice is estimated glomerular filtration rate (eGFR); however, product monographs recommend the use of the Cockcroft-Gault estimated creatinine clearance (eCrCl) for dose adjustment. Methods and Results The authors included patients enrolled in the ORBIT-AF II (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation AF II) trial. Dosing was considered inappropriate when use of eGFR resulted in a lower (undertreatment) or higher (overtreatment) dose than that recommended by the eCrCl. The primary outcome of major adverse cardiovascular and neurological events was a composite of cardiovascular death, stroke or systemic embolism, new-onset heart failure, and myocardial infarction. Among 8727 in the overall cohort, agreement between eCrCl and eGFR was observed in 93.5% to 93.8% of patients. Among 2184 patients with chronic kidney disease (CKD), the agreement between eCrCl and eGFR was 79.9% to 80.7%. Dosing misclassification was more frequent in the CKD population (41.9% of rivaroxaban users, 5.7% of dabigatran users, and 4.6% apixaban users). At 1 year, undertreated patients in the CKD group had significantly greater major adverse cardiovascular and neurological events (adjusted hazard ratio, 2.93 [95% CI, 1.08-7.92]) compared with the group with appropriate nonvitamin K oral anticoagulants dosing ( =0.03). Conclusions The prevalence of misclassification of nonvitamin K oral anticoagulants dosing was high when using eGFR, particularly among patients with CKD. Among patients with CKD, potential undertreatment due to inappropriate and off-label renal formulae may result in worse clinical outcomes. These findings highlight the importance of using eCrCl, and not eGFR, for dose adjustment in all patients with AF receiving nonvitamin K oral anticoagulants.
AbstractList	Background Nonvitamin K oral anticoagulants require dose adjustment based on kidney function.The most common estimate of kidney function employed in clinical practice is estimated glomerular filtration rate (eGFR); however, product monographs recommend the use of the Cockcroft-Gault estimated creatinine clearance (eCrCl) for dose adjustment. Methods and Results The authors included patients enrolled in the ORBIT-AF II (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation AF II) trial. Dosing was considered inappropriate when use of eGFR resulted in a lower (undertreatment) or higher (overtreatment) dose than that recommended by the eCrCl. The primary outcome of major adverse cardiovascular and neurological events was a composite of cardiovascular death, stroke or systemic embolism, new-onset heart failure, and myocardial infarction. Among 8727 in the overall cohort, agreement between eCrCl and eGFR was observed in 93.5% to 93.8% of patients. Among 2184 patients with chronic kidney disease (CKD), the agreement between eCrCl and eGFR was 79.9% to 80.7%. Dosing misclassification was more frequent in the CKD population (41.9% of rivaroxaban users, 5.7% of dabigatran users, and 4.6% apixaban users). At 1 year, undertreated patients in the CKD group had significantly greater major adverse cardiovascular and neurological events (adjusted hazard ratio, 2.93 [95% CI, 1.08-7.92]) compared with the group with appropriate nonvitamin K oral anticoagulants dosing (P=0.03). Conclusions The prevalence of misclassification of nonvitamin K oral anticoagulants dosing was high when using eGFR, particularly among patients with CKD. Among patients with CKD, potential undertreatment due to inappropriate and off-label renal formulae may result in worse clinical outcomes. These findings highlight the importance of using eCrCl, and not eGFR, for dose adjustment in all patients with AF receiving nonvitamin K oral anticoagulants.Background Nonvitamin K oral anticoagulants require dose adjustment based on kidney function.The most common estimate of kidney function employed in clinical practice is estimated glomerular filtration rate (eGFR); however, product monographs recommend the use of the Cockcroft-Gault estimated creatinine clearance (eCrCl) for dose adjustment. Methods and Results The authors included patients enrolled in the ORBIT-AF II (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation AF II) trial. Dosing was considered inappropriate when use of eGFR resulted in a lower (undertreatment) or higher (overtreatment) dose than that recommended by the eCrCl. The primary outcome of major adverse cardiovascular and neurological events was a composite of cardiovascular death, stroke or systemic embolism, new-onset heart failure, and myocardial infarction. Among 8727 in the overall cohort, agreement between eCrCl and eGFR was observed in 93.5% to 93.8% of patients. Among 2184 patients with chronic kidney disease (CKD), the agreement between eCrCl and eGFR was 79.9% to 80.7%. Dosing misclassification was more frequent in the CKD population (41.9% of rivaroxaban users, 5.7% of dabigatran users, and 4.6% apixaban users). At 1 year, undertreated patients in the CKD group had significantly greater major adverse cardiovascular and neurological events (adjusted hazard ratio, 2.93 [95% CI, 1.08-7.92]) compared with the group with appropriate nonvitamin K oral anticoagulants dosing (P=0.03). Conclusions The prevalence of misclassification of nonvitamin K oral anticoagulants dosing was high when using eGFR, particularly among patients with CKD. Among patients with CKD, potential undertreatment due to inappropriate and off-label renal formulae may result in worse clinical outcomes. These findings highlight the importance of using eCrCl, and not eGFR, for dose adjustment in all patients with AF receiving nonvitamin K oral anticoagulants. Background Nonvitamin K oral anticoagulants require dose adjustment based on kidney function.The most common estimate of kidney function employed in clinical practice is estimated glomerular filtration rate (eGFR); however, product monographs recommend the use of the Cockcroft‐Gault estimated creatinine clearance (eCrCl) for dose adjustment. Methods and Results The authors included patients enrolled in the ORBIT‐AF II (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation AF II) trial. Dosing was considered inappropriate when use of eGFR resulted in a lower (undertreatment) or higher (overtreatment) dose than that recommended by the eCrCl. The primary outcome of major adverse cardiovascular and neurological events was a composite of cardiovascular death, stroke or systemic embolism, new‐onset heart failure, and myocardial infarction. Among 8727 in the overall cohort, agreement between eCrCl and eGFR was observed in 93.5% to 93.8% of patients. Among 2184 patients with chronic kidney disease (CKD), the agreement between eCrCl and eGFR was 79.9% to 80.7%. Dosing misclassification was more frequent in the CKD population (41.9% of rivaroxaban users, 5.7% of dabigatran users, and 4.6% apixaban users). At 1 year, undertreated patients in the CKD group had significantly greater major adverse cardiovascular and neurological events (adjusted hazard ratio, 2.93 [95% CI, 1.08–7.92]) compared with the group with appropriate nonvitamin K oral anticoagulants dosing (P=0.03). Conclusions The prevalence of misclassification of nonvitamin K oral anticoagulants dosing was high when using eGFR, particularly among patients with CKD. Among patients with CKD, potential undertreatment due to inappropriate and off‐label renal formulae may result in worse clinical outcomes. These findings highlight the importance of using eCrCl, and not eGFR, for dose adjustment in all patients with AF receiving nonvitamin K oral anticoagulants. Background Nonvitamin K oral anticoagulants require dose adjustment based on kidney function.The most common estimate of kidney function employed in clinical practice is estimated glomerular filtration rate (eGFR); however, product monographs recommend the use of the Cockcroft-Gault estimated creatinine clearance (eCrCl) for dose adjustment. Methods and Results The authors included patients enrolled in the ORBIT-AF II (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation AF II) trial. Dosing was considered inappropriate when use of eGFR resulted in a lower (undertreatment) or higher (overtreatment) dose than that recommended by the eCrCl. The primary outcome of major adverse cardiovascular and neurological events was a composite of cardiovascular death, stroke or systemic embolism, new-onset heart failure, and myocardial infarction. Among 8727 in the overall cohort, agreement between eCrCl and eGFR was observed in 93.5% to 93.8% of patients. Among 2184 patients with chronic kidney disease (CKD), the agreement between eCrCl and eGFR was 79.9% to 80.7%. Dosing misclassification was more frequent in the CKD population (41.9% of rivaroxaban users, 5.7% of dabigatran users, and 4.6% apixaban users). At 1 year, undertreated patients in the CKD group had significantly greater major adverse cardiovascular and neurological events (adjusted hazard ratio, 2.93 [95% CI, 1.08-7.92]) compared with the group with appropriate nonvitamin K oral anticoagulants dosing ( =0.03). Conclusions The prevalence of misclassification of nonvitamin K oral anticoagulants dosing was high when using eGFR, particularly among patients with CKD. Among patients with CKD, potential undertreatment due to inappropriate and off-label renal formulae may result in worse clinical outcomes. These findings highlight the importance of using eCrCl, and not eGFR, for dose adjustment in all patients with AF receiving nonvitamin K oral anticoagulants.
Author	Piccini, Jonathan P. Holmes, DaJuanicia N. Levin, Adeera Fordyce, Christopher B. Yao, Ren Jie Robert Andrade, Jason G.
AuthorAffiliation	4 Montreal Heart Institute, Department of Medicine Université de Montréal Canada 5 Division of Nephrology, Department of Medicine University of British Columbia Vancouver British Columbia Canada 3 Center for Cardiovascular Innovation Vancouver Canada 1 Division of Cardiology, Department of Medicine University of British Columbia Canada 6 Centre for Health Evaluation and Outcome Sciences Vancouver British Columbia Canada 2 Duke Clinical Research Institute Durham NC
AuthorAffiliation_xml	– name: 1 Division of Cardiology, Department of Medicine University of British Columbia Canada – name: 5 Division of Nephrology, Department of Medicine University of British Columbia Vancouver British Columbia Canada – name: 4 Montreal Heart Institute, Department of Medicine Université de Montréal Canada – name: 3 Center for Cardiovascular Innovation Vancouver Canada – name: 6 Centre for Health Evaluation and Outcome Sciences Vancouver British Columbia Canada – name: 2 Duke Clinical Research Institute Durham NC
Author_xml	– sequence: 1 givenname: Ren Jie Robert surname: Yao fullname: Yao, Ren Jie Robert organization: Division of Cardiology, Department of Medicine University of British Columbia Canada – sequence: 2 givenname: DaJuanicia N. orcidid: 0000-0002-0942-1413 surname: Holmes fullname: Holmes, DaJuanicia N. organization: Duke Clinical Research Institute Durham NC – sequence: 3 givenname: Jason G. surname: Andrade fullname: Andrade, Jason G. organization: Division of Cardiology, Department of Medicine University of British Columbia Canada, Center for Cardiovascular Innovation Vancouver Canada, Montreal Heart Institute, Department of Medicine Université de Montréal Canada – sequence: 4 givenname: Adeera surname: Levin fullname: Levin, Adeera organization: Division of Nephrology, Department of Medicine University of British Columbia Vancouver British Columbia Canada – sequence: 5 givenname: Jonathan P. orcidid: 0000-0003-0772-2404 surname: Piccini fullname: Piccini, Jonathan P. organization: Duke Clinical Research Institute Durham NC – sequence: 6 givenname: Christopher B. orcidid: 0000-0002-4050-1518 surname: Fordyce fullname: Fordyce, Christopher B. organization: Division of Cardiology, Department of Medicine University of British Columbia Canada, Centre for Health Evaluation and Outcome Sciences Vancouver British Columbia Canada
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/36892077$$D View this record in MEDLINE/PubMed
BookMark	eNp1Us1u1DAQjlARLaVnbshHLru1nV9zQem2S0MrFlUFjpbjOLteJXaxnUp74xF4Ro48BZPdpWqRyCWj-X5mNP5eRgfGGhVFrwmeEpKR04_lZTkllE4xzTKcPouOKE7yCWMFPnhUH0Yn3q8xfBnN45S9iA7jrGAU5_lR9PurcFrUutNhg7RBn6y510H0UF6hhRMdKk3Q0orl0AkT0Ln1Cl10eqn3GmEaVDbrwYdeAV5KaV2jzRIFi26UAYO5dT2I1ZY667TRErqLIUjbKz8O_SyCBrFH33RYoTLARiDTtdNdB5A1O2DUj4UdApqtnAUjdKUbozboXHslvHqHKuP1cgVWc2d7tLg5q25__fhZzlFVvYqet6Lz6mT_P46-zC9uZ5eT68WHalZeT2SS4TBhJG9kzYpWSSJr2sRtlrc1i0kTE5qKPGUEgCJmOWZSJtBL0yZlbZIKQQVc-Diqdr6NFWt-53Qv3IZbofm2Yd2SCwc37RRPC5G1TGGWxDQhBNdE0DiWTV6QhGUsBq_3O6-7oe5VI-FK8CZPTJ8iRq_40t5zggkh6Xabt3sHZ78Pygfeay8VHNYoO3hO8yKlmMRJAdQ3j4c9TPmbFiCc7gjSWe-dah8oBPMxknyMJIdI8l0kQZH-o5CQrvFJYVvd_Vf3B36Q5-s
CitedBy_id	crossref_primary_10_1016_j_thromres_2023_09_005
Cites_doi	10.1056/NEJMoa1009638 10.7326/0003-4819-139-2-200307150-00013 10.1016/j.ahj.2014.04.005 10.1056/NEJMoa0905561 10.1002/phar.1282 10.7326/0003-4819-150-9-200905050-00006 10.3390/jcm8122034 10.1016/j.jacasi.2021.11.006 10.1016/j.jacc.2017.03.600 10.1016/j.cjca.2018.04.019 10.1111/jgs.16178 10.1016/j.rec.2014.06.026 10.1016/j.cjca.2020.09.001 10.1186/1471-2369-13-154 10.1016/j.ahj.2010.03.028 10.1016/j.ahj.2021.03.004 10.1016/j.jacc.2007.11.045 10.1136/openhrt-2016-000568 10.1056/NEJMoa1107039 10.1161/CIR.0000000000000665 10.1016/S0140-6736(13)62343-0 10.1161/JAHA.119.014108 10.1016/j.jacc.2016.09.966 10.2215/CJN.06870909 10.1093/jamia/ocv159
ContentType	Journal Article
Copyright	2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
Copyright_xml	– notice: 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA
DOI	10.1161/JAHA.122.026605
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
DocumentTitleAlternate	Variability in Renal NOAC Dosing and Outcomes
EISSN	2047-9980
ExternalDocumentID	oai_doaj_org_article_58a6f9e094324110b1a233cd78149693 PMC10111527 36892077 10_1161_JAHA_122_026605
Genre	Clinical Trial Research Support, Non-U.S. Gov't Journal Article
GrantInformation_xml	– fundername: ; – fundername: Bayer Canada Inc
GroupedDBID	0R~ 1OC 53G 5VS 8-1 AAMMB AAYXX AAZKR ACGFO ACXQS ADBBV ADKYN ADZMN AEFGJ AEGXH AENEX AGXDD AIAGR AIDQK AIDYY ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BCNDV CITATION DIK EBS EMOBN GODZA GROUPED_DOAJ GX1 HYE KQ8 M48 M~E OK1 RAH RNS RPM WIN 24P ACCMX CGR CUY CVF ECM EIF NPM 7X8 5PM
ID	FETCH-LOGICAL-c460t-917dcb98fec1cb2d3f67fb931d3125a7591c1c839709cc412555d59f45aa2a273
IEDL.DBID	DOA
ISICitedReferencesCount	2
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000956680700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2047-9980
IngestDate	Fri Oct 03 12:52:11 EDT 2025 Tue Nov 04 02:06:38 EST 2025 Thu Oct 02 10:57:22 EDT 2025 Thu Apr 03 07:06:04 EDT 2025 Sat Nov 29 05:05:07 EST 2025 Tue Nov 18 20:48:39 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Keywords	ORBIT‐AF II atrial fibrillation nonvitamin K oral anticoagulant renal dose adjustment
Language	English
License	This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c460t-917dcb98fec1cb2d3f67fb931d3125a7591c1c839709cc412555d59f45aa2a273
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.122.026605 For Sources of Funding and Disclosures, see page 13.
ORCID	0000-0003-0772-2404 0000-0002-4050-1518 0000-0002-0942-1413
OpenAccessLink	https://doaj.org/article/58a6f9e094324110b1a233cd78149693
PMID	36892077
PQID	2785201348
PQPubID	23479
ParticipantIDs	doaj_primary_oai_doaj_org_article_58a6f9e094324110b1a233cd78149693 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10111527 proquest_miscellaneous_2785201348 pubmed_primary_36892077 crossref_primary_10_1161_JAHA_122_026605 crossref_citationtrail_10_1161_JAHA_122_026605
PublicationCentury	2000
PublicationDate	2023-03-21
PublicationDateYYYYMMDD	2023-03-21
PublicationDate_xml	– month: 03 year: 2023 text: 2023-03-21 day: 21
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: Hoboken
PublicationTitle	Journal of the American Heart Association
PublicationTitleAlternate	J Am Heart Assoc
PublicationYear	2023
Publisher	John Wiley and Sons Inc Wiley
Publisher_xml	– name: John Wiley and Sons Inc – name: Wiley
References	e_1_3_2_26_2 e_1_3_2_20_2 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_10_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_2_2 e_1_3_2_14_2
References_xml	– ident: e_1_3_2_18_2 doi: 10.1056/NEJMoa1009638 – ident: e_1_3_2_16_2 doi: 10.7326/0003-4819-139-2-200307150-00013 – ident: e_1_3_2_6_2 doi: 10.1016/j.ahj.2014.04.005 – ident: e_1_3_2_19_2 doi: 10.1056/NEJMoa0905561 – ident: e_1_3_2_23_2 doi: 10.1002/phar.1282 – ident: e_1_3_2_17_2 doi: 10.7326/0003-4819-150-9-200905050-00006 – ident: e_1_3_2_25_2 doi: 10.3390/jcm8122034 – ident: e_1_3_2_12_2 doi: 10.1016/j.jacasi.2021.11.006 – ident: e_1_3_2_13_2 doi: 10.1016/j.jacc.2017.03.600 – ident: e_1_3_2_15_2 doi: 10.1016/j.cjca.2018.04.019 – ident: e_1_3_2_7_2 doi: 10.1111/jgs.16178 – ident: e_1_3_2_24_2 doi: 10.1016/j.rec.2014.06.026 – ident: e_1_3_2_2_2 doi: 10.1016/j.cjca.2020.09.001 – ident: e_1_3_2_9_2 doi: 10.1186/1471-2369-13-154 – ident: e_1_3_2_22_2 doi: 10.1016/j.ahj.2010.03.028 – ident: e_1_3_2_14_2 doi: 10.1016/j.ahj.2021.03.004 – ident: e_1_3_2_20_2 doi: 10.1016/j.jacc.2007.11.045 – ident: e_1_3_2_21_2 doi: 10.1136/openhrt-2016-000568 – ident: e_1_3_2_11_2 doi: 10.1056/NEJMoa1107039 – ident: e_1_3_2_3_2 doi: 10.1161/CIR.0000000000000665 – ident: e_1_3_2_4_2 doi: 10.1016/S0140-6736(13)62343-0 – ident: e_1_3_2_8_2 doi: 10.1161/JAHA.119.014108 – ident: e_1_3_2_5_2 doi: 10.1016/j.jacc.2016.09.966 – ident: e_1_3_2_10_2 doi: 10.2215/CJN.06870909 – ident: e_1_3_2_26_2 doi: 10.1093/jamia/ocv159
SSID	ssj0000627359
Score	2.3229432
Snippet	Background Nonvitamin K oral anticoagulants require dose adjustment based on kidney function.The most common estimate of kidney function employed in clinical...
SourceID	doaj pubmedcentral proquest pubmed crossref
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source
StartPage	e026605
SubjectTerms	Administration, Oral Anticoagulants - therapeutic use atrial fibrillation Atrial Fibrillation - complications Atrial Fibrillation - diagnosis Atrial Fibrillation - drug therapy Dabigatran Humans nonvitamin K oral anticoagulant ORBIT‐AF II Original Research renal dose adjustment Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - diagnosis Renal Insufficiency, Chronic - epidemiology Rivaroxaban Stroke - diagnosis Stroke - epidemiology Stroke - etiology
Title	Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT‐AF II
URI	https://www.ncbi.nlm.nih.gov/pubmed/36892077 https://www.proquest.com/docview/2785201348 https://pubmed.ncbi.nlm.nih.gov/PMC10111527 https://doaj.org/article/58a6f9e094324110b1a233cd78149693
Volume	12
WOSCitedRecordID	wos000956680700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: Directory of Open Access Journals (DOAJ) customDbUrl: eissn: 2047-9980 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000627359 issn: 2047-9980 databaseCode: DOA dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2047-9980 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000627359 issn: 2047-9980 databaseCode: M~E dateStart: 20120101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 2047-9980 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000627359 issn: 2047-9980 databaseCode: WIN dateStart: 20120101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQogL4s3yqAaJA5e0eTvmtqUbdam6W1UFeosc21EXbR20yVbqBfET-I0c-RXMxOlqF4G4cFlFsUe2Np89M_Hk-xh7naJXo1TaS2RSenGcRF4ZKuMR0zp9x1lyUXZiE3wyyc7OxPGa1BfVhDl6YPfH7SaZTCthqAAOnU3gl4EMo0hpomoSqeh4Pn0u1pIptwejW05Ez-WDUc3u--EBvfgLdzDpSEmsbs0NdWz9fwoxf6-UXHM9-T12t48ZYejmep_dMPYBu33Un4o_ZD8_YsLr-LavYGZhUttLTPkv8PIQpgsytWhaS5Kdty3s142BEZUi9zbSahjqz8umKzkHUpBYkE-DtoYTQ2PnGNqisem69lyic5guWwSsaWjQY0fQ2sCnWXsOw04NBHL6oGDuyu1cA9nTRb1soSfmhcOZtuYK9t1Z0VsY24ZeGTSQL-oLmJ7sjU9_fPs-zGE8fsQ-5KPTdwder-HgqTj1W9xLuValyCqjAlWGOqpSXpUiCnSEoZXkiQiwAeHCfaFUjPeSRCeiihMpQ4kP8THbsrU1TxmkoV_5IlOBxoUtK78MMZzShuuo1AE3ZsB2rh9poXqCc9LZmBddopMGBWGgQAwUDgMD9mZl8MVxe_y96x5hZNWNSLm7GwjVoodq8S-oDtira4QVuIjpZEZaUy-bIuRZgpFYFGcD9sQhbjVUlGYCEc4HLNvA4sZcNlvs7LwjCsftNiDZ4mf_Y_bP2Z0QAzyqvwuDF2yrXSzNS3ZLXbazZrHNbvKzbLtbhPh79HX0C5kKNuA
linkProvider	Directory of Open Access Journals
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Variability+in+Nonvitamin+K+Oral+Anticoagulant+Dose+Eligibility+and+Adjustment+According+to+Renal+Formulae+and+Clinical+Outcomes+in+Patients+With+Atrial+Fibrillation+With+and+Without+Chronic+Kidney+Disease%3A+Insights+From+ORBIT%E2%80%90AF+II&rft.jtitle=Journal+of+the+American+Heart+Association&rft.au=Ren+Jie+Robert+Yao&rft.au=DaJuanicia+N.+Holmes&rft.au=Jason+G.+Andrade&rft.au=Adeera+Levin&rft.date=2023-03-21&rft.pub=Wiley&rft.eissn=2047-9980&rft.volume=12&rft.issue=6&rft_id=info:doi/10.1161%2FJAHA.122.026605&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_58a6f9e094324110b1a233cd78149693
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9980&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9980&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9980&client=summon